Stories about Diabetic neuropathy

Subscribe to topic

Subscribe to Diabetic neuropathy

18.12.2019 – 14:07
Grünenthal Group
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...
more
02.05.2019 – 14:00
Grünenthal Group
Five young scientists win EFIC-Grünenthal Grant 2018
Brussels/Aachen (ots) - - Five creative ideas aimed at advancing research in pain have been selected to receive funding from the prestigious EFIC-Grünenthal Grant (E-G-G) 2018. - The selected teams of young scientists will start executing there innovative projects with the ambitious objective to improve the lives of people in pain. The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have ...
more
14.11.2018 – 08:45
Grünenthal Group
Grünenthal acquires Averitas Pharma and establishes commercial footprint in the US
Aachen, Germany / Morristown, New Jersey, USA (ots) - Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the ...
more

1